Making Progress Against Rare Diseases
Unmet Needs In 2020: Infographic
Executive Summary
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.
You may also be interested in...
J.P. Morgan Highlights: Major M&A Missing, But Key Takeaways For Year Ahead
The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.
Clive Dix: Industry Veteran, Vaccines Expert And Biotech Advocate
Clive Dix was awarded Scrip’s Lifetime Achievement honor jointly with his long-term colleague and friend Dame Kate Bingham in December 2021. With more than 30 years’ experience in pharma and biotech, Dix has seen the industry evolve and take on many challenges. He spoke to In Vivo about his career journey, the future of biotech and his expectations for 2022 – another year under the cloud of COVID-19.
Experience Counts For VC Success: HealthCap Hits 25 Year Mark
VC Playbook: The fundamentals do not change in life sciences investing – good science, unmet need and social responsibility.